A Seronegative CCPD Misclassified as MS: A Practical Lesson in B-Cell-Driven Disease Stabilized With Rituximab


Dörtkol O., Kara Z., Güleç B., ATALAR A. Ç., TEKEŞİN A.

Clinical and Experimental Neuroimmunology, cilt.17, sa.1, 2026 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 1
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1111/cen3.70045
  • Dergi Adı: Clinical and Experimental Neuroimmunology
  • Derginin Tarandığı İndeksler: Scopus, EMBASE, Academic Search Ultimate (EBSCO), Natural Science Collection (ProQuest), Biological Science Database (ProQuest), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
  • Anahtar Kelimeler: case report, CCPD, CIDP, demyelination, MRI, rituximab, seronegative
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background: Combined central and peripheral demyelination (CCPD) is a rare immune-mediated disorder involving both central and peripheral myelin. Recent evidence suggests that CCPD may represent a distinct clinical and immunological entity rather than a coincidental overlap between multiple sclerosis (MS) and chronic inflammatory demyelinating polyneuropathy (CIDP). Case Presentation: We report a 63-year-old seronegative female patient who had initially been followed with a diagnosis of MS and was later re-evaluated as having CCPD after developing new peripheral symptoms. Cerebrospinal fluid analysis revealed elevated protein levels with negative oligoclonal bands. Autoantibody screening, including anti-MOG, anti-MAG, AQP4, and NF155, was negative. MRI showed confluent periventricular and juxtacortical lesions consistent with central involvement. The patient showed clinical stability with no further radiological progression after rituximab therapy over an 8-month follow-up period. Conclusion: This case supports the existence of a seronegative, B-cell-mediated variant of CCPD and highlights the potential role of rituximab in achieving disease stabilization. Recognition of CCPD as a distinct diagnostic entity may prevent misclassification as MS and guide appropriate immunotherapy strategies.